Adamas Pharma Wins First FDA Nod for Parkinson's Drug

The U.S. Food and Drug Administration approved Adamas Pharmaceuticals' Gocovri for treating a side effect caused by a popular Parkinson’s drug, according to a Reuters article. As a result, the company’s shares jumped 30.9 percent.

Many patients who struggle with Parkinson’s are treated with levodopa, but that often leads to dyskinesia, causing involuntary movements that are non-rhythmic, purposeless and unpredictable.

Gocovri, previously called ADS-5102, is said to be the first drug approved by the FDA to control levodopa-induced dyskinesia (LID).

Several drugmakers are joining the growing group of protestors who are distancing themselves from the Fox News Channel shows featuring Tucker Carlson and Jeanine Pirro after the hosts were accused of making bigoted statements.

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.